TOTAL RNA SEQUENCING WITH OPTION TO INCREASE

This is a Notice of Intent, not a request for proposal. The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate on an other than full and open competition basis with Psomagen, Inc. for total RNA sequencing with an option to increase. Due to continuity protocols, and to avoid introducing variables in the testing results, we must use the same source throughout the life of the study.

The National Institute of Allergy and Infectious Diseases (NIAID), has a study to sequence RNA obtained from the PBMC’s of the same set of patients whose nasal epithelium was earlier sequenced. The purpose of this research is to understand transcriptomics signatures of asthma and asthma severity in the African Diaspora.

The RNASeq generated from the PBMCs will be compared to RNASeq generated from nasal epithelium on the same study subjects to allow NIAID to identify common and unique signatures from two different target tissues relevant to this disease. Psomagen has sequenced the RNA samples that were obtained from the Nasal epithelium from the subjects in the CAAPA study. For the uniformity and comparability, NIAID request to use Psomagen to sequence the PBMC samples so as the expand on the pre-existing resources in CAAPA.

Psomagen is ISO 9001 and ISO13485 certified to provide high quality data in our entire sample preparation and sequencing processes. Psomagen Clinical Laboratory in the US practices under CLIA certified and CAP accredited environment which assures higher standard of accuracy, reliability, and timeliness of test results. The statutory authority for this sole source requirement is 41 U.S.C.

1901 (a) (1) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide comparable services may submit a capability statement that will be considered.

The documents must be submitted via the NIAID electronic Simplified Acquisition Submission System (eSASS) website at https://esass.nih.gov, (subject line to reference NOINIAID-24-2217118 by 12:00 pm eastern standard time May 6, 2024. All vendors must register in the eSASS system to submit a quotation. Instructions on how to register / submit quotes are included on the website. Late submissions shall be treated in accordance with the solicitation provision at FAR 52.212-1(f). All responsible sources may submit an offer that will be considered by this Agency.